The firm's revenues declined on lower sales for its MassArray products and services and an increase in spending. It said that it is focusing its R&D efforts on its DNA-based Down syndrome test and has placed the RNA test on the backburner.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.